Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 2, 2014, Pages 169-174

  Relling, M V ^a   Mcdonagh, E M ^b   Chang, T ^a   Caudle, K E ^a   Mcleod, H L ^c   Haidar, C E ^a   Klein, T ^b   Luzzatto, L ^d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b STANFORD UNIVERSITY   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RASBURICASE;

DRUG CONTRAINDICATION; ENZYME ASSAY; GENETIC VARIABILITY; GENOTYPE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYTIC ANEMIA; HUMAN; INCIDENTAL FINDING; METHEMOGLOBINEMIA; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

ANIMALS; GENOTYPE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC; URATE OXIDASE;

EID: 84904857061     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.97     Document Type: Review

References (38)

1. Beutler, E. G6PD deficiency. Blood 84, 3613-3636 (1994 (Pubitemid 24362456)
2. Cappellini, M.D. & Fiorelli, G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 371, 64-74 (2008
3. Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. Bull. World Health Organ. 67, 601-611 (1989
4. Youngster, I. et al. Medications and glucose-6-phosphate dehydrogenase deficiency: An evidence-based review. Drug Saf. 33, 713-726 (2010
5. McDonagh, E.M., Thorn, C.F., Bautista, J.M., Youngster, I., Altman, R.B. & Klein, T.E. PharmGKB summary: Very important pharmacogene information for G6PD. Pharmacogenet. Genomics 22, 219-228 (2012
6. Navolanic, P.M et al. Elitek-rasburicase: An effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia 17, 499-514 (2003 (Pubitemid 36395643)
7. Pui, C.H. Rasburicase: A potent uricolytic agent. Expert Opin. Pharmacother. 3, 433-442 (2002
8. Sivilotti, M.L. Oxidant stress and haemolysis of the human erythrocyte. Toxicol. Rev. 23, 169-188 (2004 (Pubitemid 40553035)
9. Mason, P.J., Bautista, J.M. & Gilsanz, F. G6PD deficiency: The genotypephenotype association. Blood Rev. 21, 267-283 (2007
10. McDonagh, E.M., Bautista, J.M., Youngster, I., Altman, R.B. & Klein, T.E. PharmGKB summary: Methylene blue pathway. Pharmacogenet. Genomics 23, 498-508 (2013
11. Curry, S. Methemoglobinemia. Ann. Emerg. Med. 11, 214-221 (1982 (Pubitemid 12077867)
12. Skold, A., Cosco, D.L. & Klein, R. Methemoglobinemia: Pathogenesis, diagnosis, and management. South. Med. J. 104, 757-761 (2011
13. Nomenclature of glucose-6-phosphate dehydrogenase in man. Am. J. Hum. Genet. 19, 757-761 (1967
14. Minucci, A., Moradkhani, K., Hwang, M.J., Zuppi, C., Giardina, B. & Capoluongo, E. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: Review of the "old" and update of the new mutations. Blood Cells Mol. Dis. 48, 154-165 (2012
15. Yoshida, A., Beutler, E. & Motulsky, A.G. Human glucose-6-phosphate dehydrogenase variants. Bull. World Health Organ. 45, 243-253 (1971
16. Longo, L. et al. Maternally transmitted severe glucose 6-phosphate dehydrogenase deficiency is an embryonic lethal. EMBO J. 21, 4229-4239 (2002
17. Standardization of procedures for the study of glucose-6-phosphate dehydrogenase. Report of a WHO Scientific Group. World Health Organ. Tech. Rep. Ser. 366, 1-53 (1967
18. Luzzatto, L. & Poggi, V. Glucose-6-phosphate dehydrogenase deficiency. In Nathan and Oski's Hematology of Infancy and Childhood 7th edn., (eds. Meloni, D., Anderson, A.) (Saunders Elsevier, Philadelphia, 2009
19. Pamba, A. et al. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood 120, 4123-4133 (2012
20. Nkhoma, E.T., Poole, C., Vannappagari, V., Hall, S.A. & Beutler, E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-Analysis. Blood Cells Mol. Dis. 42, 267-278 (2009
21. Howes, R.E. et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: A geostatistical model-based map. PLoS Med. 9, e1001339 (2012
22. Au, W.Y., Tse, J., So, J.C., Wan, T.S. & Young, K. Unexpected glucose-6-phosphate dehydrogenase deficiency. Br. J. Haematol. 145, 680 (2009
23. Tada, K. & Hayashi, T. Erythrocyte glucose-6-phosphate dehydrogenase activity in Klinefelter's syndrome. Tohoku J. Exp. Med. 85, 248-251 (1965
24. Rinaldi, A., Filippi, G. & Siniscalco, M. Variability of red cell phenotypes between and within individuals in an unbiased sample of 77 heterozygotes for G6PD deficiency in Sardinia. Am. J. Hum. Genet. 28, 496-505 (1976
25. Algur, N., Avraham, I., Hammerman, C. & Kaplan, M. Quantitative neonatal glucose-6-phosphate dehydrogenase screening: Distribution, reference values, and classification by phenotype. J. Pediatr. 161, 197-200 (2012
26. Riskin, A., Gery, N., Kugelman, A., Hemo, M., Spevak, I. & Bader, D. Glucose-6-phosphate dehydrogenase deficiency and borderline deficiency: Association with neonatal hyperbilirubinemia. J. Pediatr. 161, 191-6.e1 (2012
27. Kaplan, M., Algur, N. & Hammerman, C. Intermediate values of glucose-6-phosphate dehydrogenase. J. Pediatr. 161, 571; author reply 571-571; author reply 572 (2012
28. Lin, Z., Fontaine, J.M., Freer, D.E. & Naylor, E.W. Alternative DNA-based newborn screening for glucose-6-phosphate dehydrogenase deficiency. Mol. Genet. Metab. 86, 212-219 (2005 (Pubitemid 41412178)
29. Weng, Y.H., Chiu, Y.W., Cheng, S.W. & Hsieh, M.Y. Risk assessment for adverse outcome in term and late preterm neonates with bilirubin values of 20 mg/dL or more. Am. J. Perinatol. 28, 405-412 (2011
30. Kaplan, M., Hammerman, C. & Beutler, E. Hyperbilirubinaemia, glucose-6-phosphate dehydrogenase deficiency and Gilbert syndrome. Eur. J. Pediatr. 160, 195 (2001 (Pubitemid 32206351)
31. May, J. et al. Red cell glucose-6-phosphate dehydrogenase status and pyruvate kinase activity in a Nigerian population. Trop. Med. Int. Health 5, 119-123 (2000 (Pubitemid 30159129)
32. Elitek [drug label] Bridgewater, NJ: Sanofi-Aventis US. http: //dailymed.nlm. nih.gov/. Accessed 16 May 2012
33. Yan, T. et al. Incidence and complete molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Guangxi Zhuang autonomous region of southern China: Description of four novel mutations. Haematologica 91, 1321-1328 (2006 (Pubitemid 44569804)
34. Matsuoka, H. et al. Seven different glucose-6-phosphate dehydrogenase variants including a new variant distributed in Lam Dong Province in southern Vietnam. Acta Med. Okayama 61, 213-219 (2007 (Pubitemid 47502134)
35. Sundy, J.S. et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA 306, 711-720 (2011
36. Kletzien, R.F., Harris, P.K. & Foellmi, L.A. Glucose-6-phosphate dehydrogenase: A "housekeeping" enzyme subject to tissue-specific regulation by hormones, nutrients, and oxidant stress. FASEB J. 8, 174-181 (1994
37. Hershfield, M.S. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin. Pharmacol. Ther. 93, 153-158 (2013
38. Pui, C.H. Urate oxidase in the prophylaxis or treatment of hyperuricemia: The United States experience. Semin. Hematol. 38, 13-21 (2001.